CymaBay Therapeutics, Inc. (CBAY)
CBAY Price and Sentiment
CBAY Latest news
CymaBay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q2 2021 Results - Earnings Call Transcript
CymaBay Reports Second Quarter and Six Months Ended June 30, 2021 Financial Results and Provides Corporate Update2021-08-12 16:06
Secured up to $100 million of additional development funding through a non-dilutive financing transaction with Abingworth
NEWARK, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, August 12, 2021 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter ended June 30, 2021 and to provide a business update.
CymaBay Therapeutics Inc (NASDAQ: CBAY) has received $100 million in non-dilutive financing from Abingworth to fund the Phase 3 development program for seladelpar in primary biliary cholangitis (PBC). Under the terms of the transaction, CymaBay will receive up to $100 million of seladelpar development costs, of which $75 million will be received in three installments over approximately six months.
Risk-sharing agreement with Abingworth will fund seladelpar Phase 3 development program for PBC
AEVA, BIDU, CBAY, DRNA and RACE have been added to the Zacks Rank #5 (Strong Sell) List on July 20, 2021.
Cymabay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q1 2021 Results - Earnings Call Transcript
Highly experienced executives, Dr. Dennis Kim as Chief Medical Officer and Lewis Stuart as Chief Commercial Officer, strengthen the management team
Proven Leader in Building Commercial Organizations to Prepare Markets and Deliver Successful Product Launches Planning for Seladelpar Launch as it Completes Development and Regulatory Submissions
NEWARK, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of biopharma veteran Thomas Wiggans and commercial leader Janet Dorling to its Board of Directors. Concurrently with these appointments, CymaBay announced that Paul F. Truex has resigned from the Board of Directors effective as of April 1, 2021 to focus on his new role as Chief Executive Officer of LQT Therapeutics.